GLP‐1 agonists may facilitate insulin entry in the brain, reduce insulin resistance, decrease neuroinflammation and restore neurogenesis in the absence of elevated peripheral inflammation suggesting that they may be useful in the treatment of non‐diabetic AD patients (Bae & Song, 2017; Cai et al., 2018). This evidence concerns the gene GCG and Alzheimer disease.